Radiation Dosimetry in Non-Hodgkin’s B-Cell Lymphoma Patients Treated with 131I-Rituximab Radioimmunotherapy

Main Article Content

Wirote Changmuang Arpakorn Kositwattanarerk Kittipong Thongklam Kanokon Poonak Putthiporn Charoenphun Thanete Doungta

Abstract

Objective: The aim of this study was to calculate a therapeutic dose of 131I-Rituximab after a tracer patient-specific dosimetry based on whole body absorbed dose of 0.75 Gy.


Methods: Eight patients (mean ± S.D. age, 59.0 ± 11.6 years) were given initial tracer activity of 131I-Rituximab intravenously. Whole body images at 10 minutes, 3 days and 6 days were used to generate the Time-activity curve (TAC). TAC was fitted by plotting Log10 of the percentage administered activity remaining with time of scan and was used for calculation of the effective half-life, residence time and therapeutic dose. The organs dose was calculated by MIRDOSE 3.1 software.


Results: The mean effective half-life was 145.7 ± 13.4 hours, whereas the residence time was 210.3 ± 19.4 hours. The mean therapeutic dose was 1.16 ± 0.16 GBq. The mean absorbed dose to liver, lungs, ovaries, red marrow, testes and total body was 0.58 ± 0.05, 0.54 ± 0.05, 0.63 ± 0.06, 0.56 ± 0.05, 0.53 ± 0.05 and 0.54 ± 0.06 mGy/MBq, respectively.


Conclusions: The whole body radiation dose using a patient-specific tracer dose calculation based on whole body absorbed dose of 0.75 Gy was appropriate for therapeutic dose calculation in Radioimmunotherapy (RIT) patient.


 

Keywords

Article Details

How to Cite
Changmuang, W., Kositwattanarerk, A., Thongklam, K., Poonak, K., Charoenphun, P., & Doungta, T. (2017). Radiation Dosimetry in Non-Hodgkin’s B-Cell Lymphoma Patients Treated with 131I-Rituximab Radioimmunotherapy. Ramathibodi Medical Journal, 40(2), 8-15. Retrieved from https://www.tci-thaijo.org/index.php/ramajournal/article/view/87519
Section
Original Articles

References

1. Juweid ME. Radioimmunotherapy of B Cell Non-Hodgkin's Lymphoma-From Clinical Trials to Clinical Preactice. J Nucl Med. 2002;43(11):1507-1529.

2. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767-1776.

3. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117(1):45-52. doi:10.1182/blood-2010-02-269753.

4. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Nucl Med. 2007;25(11):1396-1402.

5. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(27):4418-4425.

6. Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol. 2008;19(9):1629-1633. doi:10.1093/annonc/mdn172.

7. Lymphomation.org. Comparing Properties of Bexxar and Zevalin. https://www.lymphomation.org/compare-bexxar-zevalin.htm. Updated August 16, 2013. Accessed Apirl 20, 2016.

8. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm. 2003;18(4):513-524.

9. Mihailovic J. Current concepts of 131I therapy in oncology: Indications, methods and follow up. Archive of oncology. 2006;14(1-2):45-51. doi:10.2298/AOO0602045M.

10. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44(1):67-76.

11. Changmuang W, Chotipanich C, Tuntawiroon M, Chuamsaamarkkee K, Jumpee C, Wittayachokkitikhun S. First experience for internal dosimetry calculation of red marrow in Thai-neuroendocrine tumor patients treated with 131I-MIBG. J Nucl Med. 2009;50(Suppl 2):2131.

12. Calais PJ, Turner JH. Standard Operating Procedure for Prospective Individualised Dosimetry for ([131]) I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma. World J Nucl Med. 2012;11(3):110-116. doi:10.4103/1450-1147.103409.

13. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10(11):1696-711.

14. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8 Suppl):14S-20S.

15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7.

16. Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. J Nucl Med. 2001;42(3):492-8.

17. Calais PJ, Turner JH. Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety. Clin Nucl Med. 2012;37(8):732-7. doi:10.1097/RLU.0b013e31825ae6f6.

18. Kositwattanarerk A, Changmuang W, Sangsuriyan J, et al. 131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: the first case report in Thailand. J Med Assoc Thai. 2013;96(6):756-60.

Most read articles by the same author(s)